Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Regeneron Pharmaceuticals
So what: The last few days have been a wild ride for Regeneron shareholders. After soaring Wednesday on positive news related to the company's Zaltrap drug, the stock tanked yesterday on news that has negative implications for a macular degeneration treatment it is developing with Bayer.
Now what: The Food and Drug Administration is expected to decide whether to approve Regeneron's macular degeneration treatment by Aug. 20, giving the drug near-term profit potential. Lucentis, a competing treatment from Roche and Novartis
Interested in more info on Regeneron? Add it to your watchlist by clicking here.
Fool contributor Cindy Johnson does not own shares of any company named above. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.